What Have We Learned from the Shortening of Treatment for Drug-sensitive TB?

Date:

November 20, 2014 (All Day)

Dr. Richard Chaisson and Dr. Eric Nuermberger talk about what has been learned from recent phase 2 and phase 3 trials of shortening the treatment for drug-sensitive tuberculosis. 

Video/Audio/Slides

Audio-only/Slides

Projects

A Nurse Case Management Intervention to...

Dr. Farley is responsible for the overall project from design, implementation, data collection, and preparation of...

Read More

Evaluation of a novel serum biosignature for...

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites...

Read More

TBM-KIDS (India)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More